If you're holding AVEO, better to just not look today.
IrishTxAggie said:
If you're holding AVEO, better to just not look today.
Wtf happened there?IrishTxAggie said:
If you're holding AVEO, better to just not look today.
Delaying the NDA filing until Q1 2020. FDA basically told them that keeping the HR<1 at the scheduled June readout will do. So basically if they file in Q1, they believe the HR will stay below 1 in the June readout. If they don't...well hello bankruptcy.gougler08 said:Wtf happened there?IrishTxAggie said:
If you're holding AVEO, better to just not look today.
Is it happening?gougler08 said:
JD above 32 in the premarket trading, could we finally break through?
As long as the $13.60 area hard resistance holds. Huge volume Friday hit that and its held so far. Only issue from there is time value for it to lose steam.Pignorant said:
X up over $13 after earnings were better than expected.
Puts still in play for this one?
hold onto your buttsWestTexAg12 said:
So what's the play on ROKU?
Option premiums off the chartsRagoo said:hold onto your buttsWestTexAg12 said:
So what's the play on ROKU?
Earnings this weekoldarmy1 said:Option premiums off the chartsRagoo said:hold onto your buttsWestTexAg12 said:
So what's the play on ROKU?
oldarmy1 said:Option premiums off the chartsRagoo said:hold onto your buttsWestTexAg12 said:
So what's the play on ROKU?
IrishTxAggie said:Delaying the NDA filing until Q1 2020. FDA basically told them that keeping the HR<1 at the scheduled June readout will do. So basically if they file in Q1, they believe the HR will stay below 1 in the June readout. If they don't...well hello bankruptcy.gougler08 said:Wtf happened there?IrishTxAggie said:
If you're holding AVEO, better to just not look today.
Quote:
Citing the totality of the data, the FDA recommended that it not submit a marketing application at this time, remaining "concerned" with the overall survival (OS) data in the Phase 3 TIVO-3 study, specifically, that it may be worse than the comparator drug, Bayer's Nexavar (sorafenib). The second interim OS analysis, conducted in August, showed a hazard ratio of 0.99 at year 2, meaning that treatment with tivozanib reduced the risk of death by only 1% compared to sorafenib.
The agency informed the company that if it decides to file an NDA, it should include an updated statistical analysis plan with updated OS data, adding that an advisory committee review will be necessary.
If it stays under $80 into the close, it's a long way down to $70khkman22 said:
Got in on some 11/8 BYND 76 puts at $0.86. We'll see if the insider sell off continues to take it down.
khaos288 said:
32p 11/8 Uber @2.25
Uber and Lyft both feeling pain from Cali laws
Uber earnings 11/3 suffer from above
Uber lockout ends 11/6 sell off
Profit
oldarmy1 said:
WPM dropping quickly